August 2018 - Page 2 of 3 - CanadianCannabisWire

FridayAug 17, 2018 1:42 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Progress in Revolutionary Alternative to Smoking for Drug Delivery

Smoking-related deaths have reached six million a year worldwide Lexaria’s patented drug delivery platform aims to deliver commonly smoked drugs in a non-smoking form factor that sidesteps smoking’s hazards Second round of testing continues to indicate that patented DehydraTECH™ platform provides rapid delivery with high bioavailability As world drug industry regulations undergo revolutionary change and increasingly healthy populations find themselves challenged to meet the cares of old age, Canadian biotechnology company Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is forging a path that establishes it as a pioneer in the field of drug delivery platforms. Lexaria’s mission is to ensure…

ThursdayAug 16, 2018 1:47 pm

PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Medicinal Cannabis Division Targets Treatment Option for Anxiety Disorders

Anxiety is implicated in several chronic physical illnesses including heart disease, respiratory disorders and gastrointestinal conditions Scientific evidence in several studies shows that CBD exhibits anti-inflammatory and anti-anxiety properties Newly created medicinal cannabis division will focus on development of cannabinoids as preventative treatment for anxiety disorders Use of PreveCeutical’s proprietary Sol-gel nasal delivery platform for cannabinoid therapy promises ease of use, sustained release, better efficacy Preventative medicine industry represents a $3.8 trillion market Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is tackling a topic that many people hesitate to bring up – anxiety disorders, including…

MondayAug 13, 2018 12:09 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is Named for its Attention to Preventative Health Care

Private placement of $4.9 million in June 2018 Five R&D programs currently underway Preventative health care market set to reach $200 billion by 2025 PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is on a mission neatly expressed in its name and in the metaphoric maxim “an ounce of prevention is worth a pound of cure.” Yet, notwithstanding that axiom, medicinal practice and health care have been viewed, for almost a millennium, mainly as “cure,” despite always being administered with a dose of “prevention.” Now, in the 21st century, that auxiliary aspect seems to be gaining the recognition it…

MondayAug 13, 2018 11:36 am

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Human Clinical Study on TurboCBD Capsules Corroborates Earlier DehydraTECH Test Results

Significant bioavailability results were reported from LXRP’s randomized, double-blind European study that evaluated its proprietary TurboCBD capsules, powered by DehydraTECH Results corroborate and confirm in vitro and in vivo studies of DehydraTECH technology that measured high levels of drug delivery being achieved faster than with matching controls LXRP says that it is pleased that DehydraTECH has, to date, repeatedly proved evidence of success within human studies; technology earlier demonstrated ability to deliver nicotine Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is pleased to report significant bioavailability results from its randomized and double-blind European human clinical study of DehydraTECH™ powered TurboCBD™…

MondayAug 13, 2018 10:50 am

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) Investee Companies Gain Traction in US Medical Cannabis Space

FinCanna’s royalty finance model could be a game changer for companies needing capital while operating in the U.S. medical cannabis space Pilot marketing program offering HIPAA-compliant point-of-sale solution and inventory tracking system launched in California’s medical cannabis marketplace The U.S. medical cannabis market is projected to grow at 11.8 percent CAGR through 2025 from $5.1 billion to an estimated $12.5 billion in 2025 (New Frontier Data) FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF), a royalty company focused on becoming the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry, continues to gain momentum…

WednesdayAug 08, 2018 12:58 pm

Investment Researchers Peg Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) as Example of ‘Badly Mispriced’ Stock with Return Potential

Beacon Securities Limited argues that Sunniva’s Canadian greenhouse alone is worth more than its entire market cap California facility, Canadian cannabis clinics add to company’s value Sunniva also bolstered by agreement with licensed producer Canopy Growth Corp. amid heightened M&A activity in cannabis sector Cannabis supplier Sunniva Inc.’s (CSE: SNN) (OTCQX: SNNVF) strengthening foothold in California’s and Canada’s consumer-populated markets has been failing to translate to its stock price and market cap since it began trading on the Canadian Securities Exchange and the U.S. OTCQX® Best Market in January, leading investment researchers at Beacon Securities Limited (http://cnw.fm/PhE2A) to classify Sunniva’s public offering as a…

TuesdayAug 07, 2018 11:32 am

BLOCKStrain Technology Corp. (TSX.V: DNAX) Reaches Key Milestones toward Imminent Launch of Seed-to-Sale Cannabis Tracking Software

Major features finalized under aggressive deadline, with product launch mere weeks away Proprietary technology suite tracks cannabis end-to-end with blockchain-protected solution for growers, breeders Current cannabis testing system vulnerable, leaving consumers and producers exposed to risk Strategic partnership announced to implement BLOCKStrain platform’s benefits into regulatory framework for medical and adult-use cannabis in Canada Canada’s inexorable march toward full legalization of cannabis for the adult user in both the medical and recreational markets is much anticipated by the public and Vancouver, Canada-based BLOCKStrain Technology Corp. (TSX.V: DNAX). Major features of BLOCKStrain’s proprietary, end-to-end cannabis tracking platform are rapidly being finalized by…

MondayAug 06, 2018 10:04 am

Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) to Launch OKI Brand CBD-Infused Products in 3Q2018, Signs Agreement for Access to 2,400 Stores

PHVAF inks agreement with Acosta’s National Specialty Sales division to sell to 2,400 retailers across U.S., will later have access to 25,000 more supermarkets, such as Wal-Mart and Target Jim Bailey, PHVAF CEO and president, terms crossover distribution into mainstream national retailers a “significant milestone” for the CBD industry; market channel is valued at $4.1 billion OKI line to consist of CBD-infused beverages, such as iced tea and flavored infused waters, plus tinctures and capsules; it will be available to consumers in 3Q2018 Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) will launch its OKI brand of premium CBD products to…

FridayAug 03, 2018 1:58 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enabling Companies to Produce High-Quality Cannabis-Infused Products

80 percent of the company’s total revenue anticipated from the licensing of DehydraTECH™ Nuke Enterprises renewed its license, sending a strong vote of confidence in the technology Enabled GP Holdings to create a high-performing cannabis-infused beverage Biolog Inc. is developing products which will allow processors and consumers to turn almost any food or beverage into a cannabis edible Beginning production of a line of cannabis-infused alcohol-free beverages through a new licensing agreement Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator, utilizes its unique patented DehydraTECH™ delivery technology to enhance the products of its clients. This patented…

FridayAug 03, 2018 11:52 am

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Advances Controlled Synthesis of Scorpion Venom Peptides for Brain Therapies

PreveCeutical’s ‘Nature Identical™’ efforts aim to create consistently reproducible versions of found-in-nature therapeutics Company has begun engineering redesign phase of select identified peptides derived from famed scorpion venom Preventative therapeutics market expected to generate $196.9 billion in revenues by 2024, demonstrating alternative health products’ potential PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) efforts to develop a synthesized and consistently reproducible ‘Nature Identical™’ scorpion venom, popular as a pain reliever and cancer therapy, has taken a new step toward marketability as the company commences work on re-engineering venom peptide components to stabilize them. The biotech company based in British…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 905.674.5977

Month: August 2018